A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients

Trial Profile

A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Acute heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms RELAX AHF-Pan EU; RELAX-AHF-EU
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2017 Status changed from recruiting to discontinued.
    • 13 Jun 2017 This trial has been discontinued in Croatia (end date: 25 Apr 2017).
    • 03 Jun 2017 This trial has been discontinued in Greece (End date:2017-04-28) and Slovakia as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top